GLUE

Monte Rosa Therapeutics, Inc. [GLUE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GLUE Stock Summary

Top 10 Correlated ETFs

GLUE


Top 10 Correlated Stocks

GLUE


In the News

09:51 16 Apr 2024 GLUE

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why

Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

10:56 16 Apr 2024 GLUE

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

09:51 16 Apr 2024 GLUE

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why

Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

10:56 16 Apr 2024 GLUE

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

07:00 16 Apr 2024 GLUE

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim 6th Annual Biotechnology Conference (New York, NY) – Markus Warmuth, M.D., Chief Executive Officer, to participate in fireside chat, February 7, 2024, at 1:30 p.m.

07:00 16 Apr 2024 GLUE

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, November 28, 2023, at 3:30 p.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 90 days following the presentation.

07:00 16 Apr 2024 GLUE

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (virtual) – Fireside Chat, November 3, 2023, 1:00 p.m. ET Jefferies London Healthcare Conference (London, UK) – Investor meetings, November 14-15, 2023 The webcasted presentation will be accessible via the “Events & Presentations” section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 90 days following the presentation.

11:18 16 Apr 2024 GLUE

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

04:30 16 Apr 2024 GLUE

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to present at the following investor and industry events in June:

07:30 16 Apr 2024 GLUE

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:

GLUE Financial details

Company Rating
Neutral
Market Cap
361.61M
Income
-133.13M
Revenue
0
Book val./share
3.15
Cash/share
4.08
Dividend
-
Dividend %
-
Employees
133
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.98
Forward P/E
-2.91
PEG
-1.79
P/S
-
P/B
2.08
P/C
1.61
P/FCF
-3.16
Quick Ratio
7.91
Current Ratio
8.09
Debt / Equity
0.26
LT Debt / Equity
0.24
-
-
EPS (TTM)
-2.59
EPS next Y
-2.26
EPS next Q
-0.62
EPS this Y
18.47%
EPS next Y
-12.69%
EPS next 5Y
-138.61%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-17.14%
-
-
-
-
SMA20
16.67%
SMA50
40%
SMA100
133.33%
Inst Own
71.97%
Inst Trans
0.89%
ROA
-51%
ROE
-56%
ROC
-0.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
50.15M
Shs Float
31.66M
-
-
-
-
Target Price
-
52W Range
2.44-8.84
52W High
-17.75%
52W Low
+229%
RSI
48
Rel Volume
0.64
Avg Volume
138.73K
Volume
89.14K
Perf Week
-6.93%
Perf Month
16.25%
Perf Quarter
148.3%
Perf Half Y
36.23%
-
-
-
-
Beta
1.446
-
-
Volatility
0.36%, 0.61%
Prev Close
-8.74%
Price
6.58
Change
-7.58%

GLUE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.18-0.82-1.55-2.22-2.63
Operating cash flow per share
-0.14-0.52-1.28-1.96-0.85
Free cash flow per share
-0.17-0.6-1.48-2.23-1.22
Cash per share
0.140.957.445.574.52
Book value per share
-0.28-1.117.475.753.49
Tangible book value per share
-0.28-1.117.475.753.49
Share holders equity per share
-0.28-1.117.475.753.49
Interest debt per share
0.451.5401.070.9
Market cap
931.98M931.98M950.26M359.4M290.39M
Enterprise value
926.73M958.04M604.19M351.49M208.33M
P/E ratio
-116.25-25.84-13.21-3.44-2.15
Price to sales ratio
00000
POCF ratio
-150.98-40.43-16.01-3.89-6.63
PFCF ratio
-123.31-35.25-13.75-3.41-4.62
P/B Ratio
-76.72-19.132.731.321.62
PTB ratio
-76.72-19.132.731.321.62
EV to sales
00000
Enterprise value over EBITDA
-121.2-35.13-8.31-3.12-1.52
EV to operating cash flow
-150.13-41.56-10.18-3.8-4.76
EV to free cash flow
-122.62-36.23-8.74-3.34-3.32
Earnings yield
-0.01-0.04-0.08-0.29-0.47
Free cash flow yield
-0.01-0.03-0.07-0.29-0.22
Debt to equity
-1.62-1.3900.170.26
Debt to assets
1.781.3700.140.15
Net debt to EBITDA
0.69-0.964.760.070.6
Current ratio
2.271.4920.9610.795.07
Interest coverage
-7.99K00-29.860
Income quality
0.80.640.80.850.32
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.220.150.160.140.43
Capex to revenue
00000
Capex to depreciation
-19.24-6.31-4.56-3.45-3.06
Stock based compensation to revenue
00000
Graham number
1.064.5216.1216.9214.38
ROIC
-1.1-1.48-0.2-0.3-0.54
Return on tangible assets
-0.72-0.73-0.2-0.31-0.45
Graham Net
-0.39-1.287.034.192.11
Working capital
5.47M14.32M332.03M250.32M189.62M
Tangible asset value
-12.15M-48.73M347.52M271.41M179.25M
Net current asset value
-13.48M-54.52M329.85M204.91M111.71M
Invested capital
-1.62-1.3900.170.26
Average receivables
0003.83M4.08M
Average payables
05.13M6.81M7.21M9.51M
Average inventory
000480K480K
Days sales outstanding
00000
Days payables outstanding
16.2K4.8K1.12K335.28654.21
Days of inventory on hand
00040.940
Receivables turnover
00000
Payables turnover
0.020.080.331.090.56
Inventory turnover
0008.920
ROE
0.660.74-0.21-0.39-0.76
Capex per share
-0.03-0.08-0.21-0.27-0.37

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.59-0.6-0.71-0.7-0.58
Operating cash flow per share
-0.49-0.47-0.51-0.50.52
Free cash flow per share
-0.64-0.66-0.64-0.530.49
Cash per share
5.384.74.113.584.08
Book value per share
5.554.944.323.73.15
Tangible book value per share
5.554.944.323.73.15
Share holders equity per share
5.554.944.323.73.15
Interest debt per share
10.920.950.930.81
Market cap
372.08M384.42M338.61M238.61M321.64M
Enterprise value
364.17M378.73M338.62M225.96M239.58M
P/E ratio
-3.2-3.22-2.41-1.71-2.42
Price to sales ratio
00000
POCF ratio
-15.53-16.42-13.37-9.6610.85
PFCF ratio
-11.91-11.8-10.64-9.0511.51
P/B Ratio
1.371.581.581.291.79
PTB ratio
1.371.581.581.291.79
EV to sales
00000
Enterprise value over EBITDA
-11.31-11.13-9.47-6.11-7.26
EV to operating cash flow
-15.2-16.18-13.37-9.158.08
EV to free cash flow
-11.66-11.62-10.64-8.578.57
Earnings yield
-0.08-0.08-0.1-0.15-0.1
Free cash flow yield
-0.08-0.08-0.09-0.110.09
Debt to equity
0.170.190.220.250.26
Debt to assets
0.140.150.170.180.15
Net debt to EBITDA
0.250.1700.342.49
Current ratio
10.7911.7310.98.095.07
Interest coverage
-16.3336.64000
Income quality
0.780.730.720.71-0.89
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.30.390.260.07-0.06
Capex to revenue
00000
Capex to depreciation
-6.8-7.98-4.68-0.9-0.91
Stock based compensation to revenue
00000
Graham number
8.628.198.327.646.43
ROIC
-0.08-0.09-0.12-0.13-0.13
Return on tangible assets
-0.08-0.1-0.13-0.14-0.11
Graham Net
4.053.422.812.231.9
Working capital
250.32M220.04M189.02M160.3M189.62M
Tangible asset value
271.41M243.73M213.65M184.52M179.25M
Net current asset value
204.91M175.25M143.14M115.33M111.71M
Invested capital
0.170.190.220.250.26
Average receivables
12.61M4.91M1.66M724K399.5K
Average payables
8.81M7.62M6.35M5.4M8.33M
Average inventory
480K960K480K00
Days sales outstanding
00000
Days payables outstanding
263.83577.22343.44269.9543.71
Days of inventory on hand
32.2175.07000
Receivables turnover
00000
Payables turnover
0.340.160.260.330.17
Inventory turnover
2.791.2000
ROE
-0.11-0.12-0.16-0.19-0.19
Capex per share
-0.15-0.19-0.13-0.03-0.03

GLUE Frequently Asked Questions

What is Monte Rosa Therapeutics, Inc. stock symbol ?

Monte Rosa Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol GLUE

What is Monte Rosa Therapeutics, Inc. stock quote today ?

Monte Rosa Therapeutics, Inc. stock price is $6.58 today.

Is Monte Rosa Therapeutics, Inc. stock public?

Yes, Monte Rosa Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap